Cardiovascular Disease

FDA Fast Tracks Empagliflozin to Improve Outcomes Following Heart Attack

September 18, 2020

Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.

Study: Use of Azithromycin With QT Prolonging Drugs Linked to Cardiac Events

September 18, 2020

A study compared cardiac events associated with azithromycin versus amoxicillin.

Study: Gut Microbiome Data May Be Useful in Screening for Heart Disease

September 10, 2020

The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.

FDA Approves New Doses of Dulaglutide for the Treatment of Type 2 Diabetes

September 08, 2020

Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.

Study: No Link Between Antihypertensive Medications and Cancer Risk

September 03, 2020

There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.

Dapagliflozin Reduces Risk of Kidney Failure, Death in Chronic Kidney Disease

August 31, 2020

Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.

Empagliflozin Reduces Heart Failure Hospitalization, Death Risk in Phase 3 Trial

July 31, 2020

Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.

Study Suggests Azithromycin Associated With Heart Death Risk

July 13, 2020

Azithromycin may be linked to a greater risk of cardiovascular death, according to a recent study.

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

July 03, 2020

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress.

Risk of Death By Heart Failure Increases With Recent Diagnosis of Type 2 Diabetes

July 02, 2020

Individuals recently diagnosed with type 2 diabetes were more likely to die from heart failure than any other cardiovascular disease, a study found.

FDA OKs Ticagrelor Indication to Reduce Risk of First Heart Attack, Stroke in Patients With High-Risk CAD

June 01, 2020

This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.

Analysis: Women, Older Adults Underrepresented in Cholesterol Drug Trials

May 25, 2020

Women and older adults are underrepresented in clinical trials evaluating cholesterol medications, according to a new study published in JAMA Network Open.

Study: Heart Disease Risk Associated With Cognitive Decline

May 20, 2020

Monitoring and controlling heart disease may be crucial in supporting cognitive health later in life.

No Short-Term Cognitive Harm From Low LDL-C Levels Achieved With Evolocumab

May 15, 2020

A new study found that the use of PCSK9 inhibitors with maximally tolerated statins does not negatively affect the mental cognition of patients.

NYU Study Finds High Blood Pressure Medications Use Safe with COVID-19

May 06, 2020

Results of the study showed that antihypertensive medications do not put individuals at increased risk for COVID-19.

FDA OKs Dapagliflozin for Heart Failure With Reduced Ejection Fraction

May 06, 2020

Officials with the FDA have approved dapagliflozin (Farxiga, AstraZeneca) to reduce the risk of cardiovascular death and hospitalization in adults with heart failure with reduced ejection fraction, with and without type 2 diabetes.

US Rural Communities Face Disparities in Heart Disease Outcomes

April 23, 2020

Two new studies underscore health disparities in rural United States affecting mortality rates associated with cardiovascular disease.

Bempedoic Acid Tablets Now Available in Pharmacies

April 01, 2020

Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.

Ticagrelor Monotherapy Shows Cardiovascular Benefit in Patients with Diabetes

March 31, 2020

Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.

Alirocumab Evaluated for Treatment of Homozygous Familial Hypercholesterolemia

March 31, 2020

Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.